Portfolio data

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

• Operating News
• Gene therapy
• Freeline Therapeutics

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

• Gene therapy
• Freeline Therapeutics

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

• Biologics
• Anaveon

Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM

• Gene therapy
• Freeline Therapeutics

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

• Cell therapy
• Autolus